If you have breathing problems caused by certain lung conditions, your doctor may prescribe Spiriva for you. Spiriva is a prescription drug that comes in two forms. The form your doctor prescribes ...

Spiriva (tiotropium bromide) is a prescription drug that’s used to treat COPD and asthma. The drug comes in an inhaler. It’s usually used once per day. Spiriva is a prescription drug that comes in two ...

Inhalers like Spiriva and Advair are too expensive for many Medicare beneficiaries with chronic obstructive pulmonary disease, reports Kaiser Health News. Here are four things to know. 1.

Patients whose asthma symptoms are only mild and intermittent usually don’t need daily asthma medications. They just use a rescue inhaler, like albuterol, whenever symptoms come up. Patients with ...

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...

March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker ...

Inhaler drugs used by millions of people with emphysema and bronchitis may slightly raise the risk for heart attacks and even death, a study suggests. The results aren't conclusive and inhalers ...

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...

Lupin has received the Food and Drug Administration’s permission for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic of Boehringer Ingelheim’s Spiriva HandiHaler. The ...

Inhaler drugs used by millions of people with emphysema and bronchitis may slightly raise the risk for heart attacks and even death, a study suggests. The results aren't conclusive and inhalers ...

In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...